Objectives: To investigate the therapeutic efficacy, toxicity profile and quality of life in locally advanced cervical carcinoma treated with concurrent chemoradiation therapy (CCRT), preoperative chemoradiation (PCRT) and preoperative chemotherapy (PCHEMO) followed by surgical implications Materials and methods: A total of (N = 100) locally advanced cervical cancer patients (FIGO stages IB2, IIA2 and IIB) was treated between June 2014 to March 2018, Out of 100 patients, 33 patients treated with CCRT arm (50Gy EBRT and 21Gy brachytherapy), 33 patients treated with PCRT arm (50Gy EBRT) followed by radical hysterectomy, 34 patients with PCHEMO arm followed with radical hysterectomy using 3 weekly cisplatin (75 mg/m 2 and paclitaxel (175 mg/m 2 ). Patient's Quality life was recorded with a standard questionnaire. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software version 22.
INTRODUCTION
Carcinoma of the uterine cervix is one of the 7th most common disease worldwide and considered as a malignant disease among the South Indian women with an affected population rate of about 19.4-43.5/100,000/ year. 1, 2 Locally advanced cervical tumors (characterized by FIGO stages IB2, IIA2, IIB) forms a particular subset of "curable" disease having greater 5-year survival rates (around 70%) with satisfactory treatment. 3 Concurrent cisplatin-based chemoradiotherapy is considered as the standard treatment for locally advanced cervical malignancies based on five clinical trials (GOG 85, radiation therapy oncology group RTOG 9001, GOG 123, GOG 120, SWOG 8797). 4, 5 Conversely, when pelvic recurrences develop, the morbidity of salvage surgery after Irradiation is frequently greater than the morbidity of salvage irradiation following radical surgery. The benefits of downsizing the disease by using PCHEMO or preoperative chemoradiotherapy without using brachytherapy are appealing and also open up a totally new outlook in radical treatment for curable locally advanced cervix malignancies. Radical hysterectomy after chemoradiation therapy without brachytherapy has been appeared to come up with similar outcomes with concurrent chemoradiation. 6 This strategy is more attractive in low and middle-income countries wherein the cervix related cancers burden is higher and also brachytherapy resources are limited. Numerous studies demonstrated that cisplatin and paclitaxel with concurrent radiotherapy have offered to raise response rates and desired tolerability. [7] [8] [9] [10] [11] [12] The aim of this interim analysis was to investigate the therapeutic efficacy, toxicity profile, and quality of life in locally advanced cervical carcinoma treated with CCRT, PCRT, and PCHEMO followed by surgical implications.
MATERIALS AND METHODS

Inclusion Criteria
(a) Histologically confirmed patients with cervical squamous cell carcinoma (FIGO stages IB2, IIA2, and IIB); (b) age 18-65 years; (c) ECOG performance score less than or equal to 2.
Exclusion Criteria
Patients with (a) non-squamous histologies; (b) other systemic diseases, comorbidities precluding full participation in this trial; (c) concomitant treatment with any experimental drugs; (d) pregnant or nursing women; (e) previous irradiation or concomitant malignant diseases All patients were evaluated before starting treatment with history and physical examination (examination under anesthesia to confirm the stage), biopsy, complete blood analysis, chest X-ray, ultrasonography (USG) abdomen and pelvis, CECT abdomen and pelvis, Cystoscopic examination (for tumors involving anterior fornix) and proctoscopy examination (tumors involving posterior fornix).
Treatment Schemes and Response Evaluation
The patients were randomized to three arms as standard CCRT, PCRT followed by a radical hysterectomy and PCHEMO followed by radical hysterectomy. For CCRT arm patients, cisplatin (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) were given with 3 weeks interval between the two cycles along with concurrent Radiotherapy of 50 Gy EBRT (2 Gy of 25 #) followed by brachytherapy of 21 Gy (7 Gy for 3 doses) completed within 8 weeks. For PCRT arm patients, cisplatin (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) were given with 3 weeks interval between the two cycles along with concurrent Radiotherapy of 50 Gy EBRT (2 Gy of 25 #) within a time span of 5 weeks and followed by Radical hysterectomy within 3 weeks after completion of radiotherapy, for PCHEMO arm patients, cisplatin (75 mg/m 2 ) and paclitaxel (175 mg/m 2 ) was given with 3 weeks interval for 3 cycles followed by radical hysterectomy within 3 weeks after completion of chemotherapy. During the course of treatment, all the patients underwent weekly hematology as well as blood chemistry laboratory tests for safety and dosage modification purposes. Treatment response and operability were evaluated by WHO criteria with physical examinations (examination under anesthesia at the time of radical hysterectomy) and imaging before brachytherapy, after Neo-adjuvant chemoradiotherapy and neoadjuvant chemotherapy in CCRT, PCRT and PCHEMO arms respectively. Patients with advancing disease were termed as treatment failure and taken care of with conventional chemoradiotherapy. Safety was compared by documenting clinical adverse events (AEs) by utilizing the National Cancer Institute Common Toxicity Criteria (version 3.0). Quality of life was assessed by means of two validated questionnaires (EORTC QLQ-C30 and EORTC QLQ-CX24) formulated by the European Organization for Research and Treatment of Cancer (EORTC). The association of clinical manifestations between the two groups was determined by t test for continuous variables, and Pearson's Chi-square test was adapted to estimate the associations between independent variables. A probability (p) value of < 0.05 was regarded as statistically significant. All statistical comparisons were performed using IBM SPSS version 22.0. Bonferroni adjusted Mann-Whitney test was used for various correlations in the evaluation of personal gratifications among three treatment arms.
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RESULTS
Patients' Characteristics
From July 2014 to March 2018, 100 women with age from 18 to 65 years old were enrolled and randomly allocated to CCRT arm (n = 33), PCRT arm (n = 33) and PCHEMO arm (n = 34). Of 33 patients randomized to CCRT arm, 6% defaulted during treatment (EBRT) and 6% defaulted for brachytherapy. Of 33 patients randomized to PCRT arm, 6% were defaulted for surgical treatment (after completing EBRT and two cycles of chemotherapy) and of 34 patients randomized to PCHEMO arm, 3% defaulted for surgery.
The follow-up period was until June 2018 with a median follow-up period of 28 months. Clinical characteristics were well adjusted at baseline between treatment arms and depicted in Table 1 .
JSAFOG
There was no statistically significant difference between age group, FIGO stage and performance status of the patients dispersed among three groups (p >0.05).
Oncological Outcomes
The overall response rate for CCRT, PCRT and PCHEMO arm patients were 97%, 94%, and 88%, respectively. Complete clinical response was seen in 72%, 45% and 26% of CCRT, PCRT and PCHEMO arms respectively. Partial clinical response was seen in 12%, 42% and 59% of CCRT, PCRT and PCHEMO arms respectively. At the time of response assessment 3% of CCRT,6% of PCRT and 12% patients of PCHEMO arms had progressive disease and changed over to Radical chemoradiation treatment.
At the time of this interim analysis, 70% of CCRT, 88% of PCRT and 85% of PCHEMO arm patients were alive without disease and 12% of CCRT and 6% of PCRT arms 0% of PCHEMO were dead. Of 85% alive patients in PCHEMO arm, 9% had local and 3% had distant recurrence who were treated with surgical/medical methods. Of these alive patients, 2 of CCRT and 4 of PCHEMO arm patients had recurrent disease. Two patients of CCRT arm expired due to distant recurrence. No death was noted in PCHEMO arm.
Clinical response rates among the treatment arms were found statistically significant (p = 0.0022), as shown in Table 2 .
Pathological Outcomes
Pathological Response Rate
Sixty-three percent of PCRT and 27% of PCHEMO patients had a complete pathological response which shows a statistically significant difference (p = 0.0016). Unlike in PCRT arm patients, where no positive lymph node disease, 6 of PCHEMO arm patients had lymph nodal positive disease (0% vs. 21%). there was no statistically significant relationship found between 2 arms in Lymphovascular space invasion and depth of stromal invasion. In both arms, vaginal margins and parametrial margins were not involved by the tumor cells (Table 3 ).
Perioperative Outcomes
Totally 58 patients were operated from PCRT and PCHEMO arms including 29 patients in each arm. Mean duration of hospital stay for both arms were similar (14 days) but the operating time was longer for PCRT patients than PCHEMO patients (170 mins vs.155 mins) (p >0.05). Also, the conversion rate from laparoscopic to open radical hysterectomy was higher among PCRT than PCHEMO arm patients (21% vs. 18%) (p > 0.05). There was no statistically significant difference found in the average amount of blood loss during surgery even though PCHEMO arm patients bled more than PCRT arm patients (255 mL vs. 275 mL). 
Postoperative Outcomes
Both PCRT and PCHEMO arm patients tolerated the surgery well and no treatment-related death was reported. Equal number of patients had Urinary tract infection (6%) and sustained urinary bladder injury (3%) but PCRT patients had significantly increased incidence of acquisition of Delayed Urinary bladder control (18% vs. 10%) than PCHEMO arm patients.3% of PCRT arm patients had rectum injury, and 3% of PCHEMO arm patients had an incisional hernia within 6 months.
Overall there were no statistically significant postoperative morbidities between the two arms ( Table 3) .
TOXICITY PROFILE
There were no treatment-related deaths. The types and frequencies of adverse effects are shown in Table 4 .
Eleven percent of CCRT, 9% of PCRT and 13% of PCHEMO patients had grade 3 anemia, 8% of CCRT, 5% of PCRT and 8% of PCHEMO had grade 3 leukopenia, 3% of CCRT, 2% of PCRT and 2% of PCHEMO had grade 3 thrombocytopenia, 6% of CCRT, 5% of PCRT and 4% of PCHEMO had grade 3 neutropenia during treatment. 7% of CCRT, 6% of PCRT and 6% of PCHEMO patients had grade 3 nausea and vomiting. Thirty-five percent of CCRT, 28% of PCRT and 32% of PCHEMO Patients had Grade 2 alopecia. Two percent of arm CCRT, 3% of PCRT and 6% of PCHEMO Patients had grade 3 hypersensitive reactions 2% of CCRT, 2% of PCRT and 2% of PCHEMO patients had grade 3 ototoxicity, 10% of CCRT, 8% of PCRT and 11% of PCHEMO patients had grade 3 peripheral neuropathy during treatment.
Radiotherapy-induced short-term severe toxicities reported in 14 patients. Six percent of CCRT and 3% of PCRT had grade 3 proctitis 12% of CCRT and 6% of PCRT.
Patients had grade 3 cystitis. grade 3 skin reactions reported in 6% patients and 3% patient of CCRT and PCRT respectively. Lymphedema reported in a higher number, 4 pts (12%) in PCRT than CCRT (1 pt.) and arm PCHEMO (1 pt).
Quality of Life
Results Eortc QLQ-30
Of total 100 patients incorporated in this interim analysis, total 81 (25 from CCRT, 27 from PCRT and 29 patients from PCHEMO arm fulfilled the list of questions.
One question-form was analyzed per patient by the end of three months after completion of respective 2 (6%) 3 (10%) 1 (3%) 0 (0%) 1 (3%) * * * * * *Small sample size and outcomes are not mutually exclusive, statistical tests could not be applied treatment method. For items relating to sexual performance, only sexually active women (13 from CCRT, 16 from PCRT and 11 from PCHEMO arms) replied for the questions. For the items relating to functioning scales, women in CCRT arm disclosed lower scores for physical and social functioning and women in PCHEMO arm revealed reduced emotional functioning and global health QOL. There was no significant difference among symptom scales, but CCRT arm patients disclosed an increased degree of symptom experience, difficulties in relation to sexual functioning/vaginal functioning and sexual agony. Women in PCHEMO arm disclosed lot more sexual activity and Lymphedema was more frequently recorded in PCRT arm patients. Peripheral neuropathy was more experienced by the patients in PCHEMO arm (Table 5) .
Bonferroni Adjusted Mann-Whitney Test for Multiple Comparison
There was significant declination of physical functioning among CCRT patients than other two arms and poor sexual functioning among patients of CCRT and PCRT than PCHEMO arm patients. 
DISCUSSION
Multimodality treatment modalities have focused on radical concurrent chemoradiotherapy, preoperative chemoradiotherapy followed by radical surgery and PCHEMO followed by radical surgery in recent years. [13] [14] [15] [16] [17] [18] To our knowledge, this is the first study from our institution exploring the efficacy of preoperative chemoradiotherapy and PCHEMO followed by radical surgery having conventional chemoradiation as the control arm.
Concurrent Chemoradiation Arm
A study by Brunner et al. showed 72% of patients with stage II B cervix malignancies were treated with definitive chemoradiation. 13 Also, when studied among Southeast Asian population, radical surgeries has been considered as better effective treatment strategy rather than concurrent chemoradiation. But various studies need to be explored to know the efficacy of surgical treatment benefits for these patients. 
Preoperative Chemoradiotherapy
In phase III randomized controlled trial performed by Cetina et al. in stage IB2 to II B patients using gemcitabine and cisplatin, 72% had a complete pathological response, and 22% had a partial pathological response along with 66% f patients with the microscopic disease. Our cohorts showed 63% and 23% complete and partial pathological response, respectively. About 2.3% had positive parametrial margin, and 10% had lymph nodepositive disease. But none of our study population had positive parametrial margins and positive lymph node diseases. The median length of hospital stay was 5 days (4-6 days), median operative duration was 4 hours (4-6 hours), median blood loss was 450 mL and 3.4% had a vascular injury. 1.5% had a urethral injury and 2.3% had a ureteral injury. 1,5% had wound dehiscence, and 1.5% had unilateral lymph cysts. Our clinical trial outcomes revealed 3% of urinary bladder and 3% of rectum injury. Furthermore, less amount of blood loss and less duration of surgery in comparing with L.cetina et al. results.
Similarly, a prospective analysis performed by Huguet et al., in which all the patients were given a tumor-free resection margins 19 and at histological assessment complete response was recognized in 54.5%, cervical microscopic disease with significant tumour cells <5 mm in dimension was identified in 17,5% and cervical residual disease >5 mm in dimension was identified in 28% of patients. However, when zero vaginal, as well as the parametrial residual disease, was noted which is similar to our study results. 7.8% of patients were been treated with bilateral pelvic lymph node dissection came up with pelvic lymph node-positive disease, 1.29% with isolated central recurrence, 3.89% with pelvic nodal recurrence, 3.89% with isolated metastatic diseases, 6.49% were with pelvic recurrences with synchronous metastasis as well as 1.29% metastasis with synchronous paraaortic nodal metastasis. Hardly any treatment-related deaths were noted. Chemotherapy side-effects, as well as acute radiation side-effects, were tolerable with a minimal number of cases of serious grades 3 -4 acute side effects. 20 Our findings having said that, despite achieving a path complete response rate of 63% which is within the range 52-77.5%, signifies that there is a definite role of radical surgery after chemoradiation. 21 Not surprisingly, many appealing challenges were evolved from our analysis. First, an RH after chemoradiation is feasible as well as not harmful to the patients. Operative risks are within the spectrum documented even for radical surgery performed as primary treatment of early-stage cervical cancer. additionally, a tendency for significantly fewer rates of long-term toxic outcomes. Second, the chemoradiation regimen of 3 weekly cisplatin-paclitaxel is well tolerated.
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Preoperative Chemotherapy Arm
This strategy was based on neoadjuvant chemotherapy's "ability to downstage disease, facilitate surgical resection and potentially eradicate systemic metastasis,"
In a study conducted by Park et al., clinical phase II trial showed neoadjuvant paclitaxel and cisplatin, clinical responses occurred in 90.7% of patients, including 39.5% with complete response, 11.6% with a pathologically determined complete response, 51.2% with a partial response and 9.3% of patients showed stable disease and none of them demonstrated active disease. Besides, Hematologic toxicity was noted in 39.5% of patients and most of them observed was anemia, but there were nil patients observed with grades 3 or 4 toxicities. But when observed grade 1 peripheral neuropathy was seen in 29 patients despite there is no delayed treatment of toxicities. 23 In Similar to Modaress et al. study, our cohorts experienced 21% lymph node positive diseases, but in contrast, no single patient had parametrial positive diseases.
A recently published randomized controlled trial (RCT) by Gupta et al. from Tata Memorial hospital comparing neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus CTRT in patients with stage IB2 to IIB squamous carcinoma of cervix showed that neoadjuvant chemotherapy arm patients experiencing a significantly higher rate of grades 3-4 thrombocytopenia within 42 days than the chemoradiation-treated patients but a lower rate of grades 1-2 symptoms such as diarrhea, dysuria, skin reactions, and renal toxicity. After 3 months, CCRT was associated with higher rates of rectal, bladder, vaginal, and other toxicities than neoadjuvant chemotherapy. 25 Our cohorts' toxicity profiles are staying in parallel with this study population.
Pertaining to the quality of life, in our interim analysis, there seemed to be no significant difference among symptom scales, but CCRT patients disclosed considerably more amount of symptom experience, difficulties in sexual functioning/vaginal functioning and sexual agony. However, Women in PCHEMO arm disclosed an increase in sexual activity. Lymphedema was more frequently noted in PCRT arm patients. Peripheral neuropathy was highly experienced among the patients in PCHEMO arm.
Similar to our study, showed long-term morbidity as well as better quality of life among cancer survivors. Among which 64% were found to be sexually active, 67% responded with radical hysterectomy and 50% with primary radiation therapy. 26 However, our study also showed lower scores among patients treated with CCRT having social, functional and financial difficulties. Furthermore, Women treated with CCRT showed higher level of symptom experience, sexual or vaginal functioning as well as sexual worry. Also,women treated with PCHEMO followed by radical hysterectomy also showed higher sexual activity and lymphedema as well as peripheral neuropathy. It was also observed that sexual activity in women with increased age and longer follow up study showed effective positive results on sexual activity. Thus, from our study, we observed equivalent therapeutic, better toxicity profile and quality of life among patients treated with peroperative chemoradiation followed by radical surgery than the standard concurrent chemoradiation arm patients. Even though the patients treated with preoperative chemotherapy in this interim analysis had good quality of life than the other two arms, almost half of them treated with adjuvant vault brachytherapy during treatment, hence its therapeutic efficacy should be viewed with caution.
CONCLUSION
Though it is premature to decide on this interim report, results show that chemoradiation without brachytherapy followed by surgery has been learned to have equivalent outcomes as well as associated with tolerable morbidity. It seems sensible to make use of a modified therapeutic protocol of chemoradiation followed by radical hysterectomy as an alternative treatment option in low-resource countries wherein brachytherapy is not easily accessible. Long-term outcomes of this randomized control trial are currently being evaluated.
CLINICAL SIGNIFICANCE
This approach could be feasible in developing countries with higher incidence of cervical cancers wherein brachytherapy resources are scarce.
